Pfizer/Wyeth Will Produce (Incremental) Growth, Pfizer Assures Investors
This article was originally published in The Pink Sheet Daily
Pfizer addresses investor concerns over the $68 billion mega merger at a follow up meeting Jan. 27.
You may also be interested in...
Merger propels Pfizer ahead in biotechnology and paves the way for the drug giant to navigate the loss of Lipitor in 2011.
Revlimid, Copaxone, Sensipar, Enbrel, Acthar Gel and Gleevec will be the subject of a US House Committee on Oversight and Reform in an upcoming drug price hearing.
Pfizer was heavily invested in immuno-oncology combinations five years ago, but following setbacks, the pipeline has shifted considerably, shaped partly by the acquisition of Array.